The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move that strengthens the company's position in the oncology sector, Gilead stock rose 3.5% after its drug Trodelvy received FDA and EU approval for first-line treatment of advanced triple-negative breast cancer. According to reports, HSBC upgraded GILD to 'Buy' with a price target of $155, citing oncology catalysts and advancements in HIV therapies. This regulatory milestone expands the addressable market for the drug, both as a monotherapy and in combination treatments.
This approval places Gilead in a strategic position alongside industry peers like Merck, as it facilitates the use of Trodelvy in combination with Merck’s blockbuster Keytruda. Trodelvy has shown consistent growth, with annual sales reaching $1.1 billion in 2023 per company earnings reports, supporting Gilead's pivot toward oncology to diversify its revenue beyond its core HIV franchise. Per market data, analysts are focused on how these new indications will drive long-term valuation and offset legacy product declines.
At the close on July 6, 2026, GILD stood at $129.61, while MRK closed at $126.78. Investors in the biotech space are now looking ahead to broader economic catalysts, including the upcoming Eurozone Inflation Rate (CPI) data, which may influence market sentiment and discount rates for high-growth pharmaceutical stocks.